|
|
纳米药物重塑TAMs用于增强癌症免疫治疗的研究进展
|
Abstract:
癌症免疫疗法已成为一种新型癌症治疗方法，而复杂的肿瘤微环境(Tumor microenvironment, TME)极大限制其临床应用。肿瘤微环境的重要组成部分是肿瘤相关巨噬细胞(Tumor-associated Macrophages, TAMs)，它们通常与不良预后相关，并已成为增强癌症免疫疗效的有希望的靶标。最近，由于纳米颗粒独特的物理化学特性，将免疫治疗与纳米递送系统联合使用可实现更高的疗效。在这篇综述中，我们主要描述了纳米药物重塑TAMs用于增强癌症免疫治疗的策略，包括抑制TAMs被招募到肿瘤部位、清除TAMs、将M2型TAMs重编程为M1型TAMs、调节TAMs对肿瘤细胞的吞噬能力，还描述了目前工程化巨噬细胞的研究现状。
Cancer immunotherapy has become a new type of cancer treatment, and the complex tumor microenvironment (TME) greatly limits its clinical application. Tumor-associated macrophages (TAMs), as an important component of the tumor microenvironment, are usually associated with poor prognosis and have become promising targets for enhancing the immune efficacy of cancer. Recently, due to the unique physical and chemical properties of nanoparticles, the combination of immunotherapy and nano-delivery systems can achieve higher efficacy. In this review, we mainly described the strategies of reshaping TAMs with nano-drugs to enhance cancer immunotherapy, including inhibiting the recruitment of TAMs to tumor sites, clearing TAMs, reprogramming M2-type TAMs into M1-type TAMs, regulating the phagocytic ability of TAMs to tumor cells, and also described the current research status of engineered macrophages.
| [1] | Min, H.-Y. and Lee, H.-Y. (2022) Molecular Targeted Therapy for Anticancer Treatment. Experimental & Molecular Medicine, 54, 1670-1694. https://doi.org/10.1038/s12276-022-00864-3 |
| [2] | Ke, X. and Shen, L. (2017) Molecular Targeted Therapy of Cancer: The Progress and Future Prospect. Frontiers in Laboratory Medicine, 1, 69-75. https://doi.org/10.1016/j.flm.2017.06.001 |
| [3] | Gajewski, T.F., Schreiber, H. and Fu, Y.X. (2013) Innate and Adaptive Immune Cells in the Tumor Microenvironment. Nature Immunology, 14, 1014-1022. https://doi.org/10.1038/ni.2703 |
| [4] | Cheng, Y.Q., Wang, S.B., Liu, J.H., et al. (2020) Modifying the Tumour Microenvironment and Reverting Tumour Cells: New Strategies for Treating Malignant Tumours. Cell Proliferation, 53, e12865. https://doi.org/10.1111/cpr.12865 |
| [5] | Jin, Y., Huang, Y., Ren, H., et al. (2024) Nano-Enhanced Immunotherapy: Targeting the Immunosuppressive Tumor Microenvironment. Biomaterials, 305, Article 122463. https://doi.org/10.1016/j.biomaterials.2023.122463 |
| [6] | Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013 |
| [7] | Komohara, Y., Fujiwara, Y., Ohnishi, K., et al. (2016) Tumor-Associated Macrophages: Potential Therapeutic Targets for Anti-Cancer Therapy. Advanced Drug Delivery Reviews, 99, 180-185. https://doi.org/10.1016/j.addr.2015.11.009 |
| [8] | Bingle, L., Brown, N.J. and Lewis, C.E. (2002) The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies. The Journal of Pathology, 196, 254-265. https://doi.org/10.1002/path.1027 |
| [9] | Guerriero, J.L. (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends in Molecular Medicine, 24, 472-489. https://doi.org/10.1016/j.molmed.2018.03.006 |
| [10] | Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61. https://doi.org/10.1016/j.immuni.2014.06.010 |
| [11] | Mantovani, A., Marchesi, F., Malesci, A., et al. (2017) Tumour-Associated Macrophages as Treatment Targets in Oncology. Nature Reviews Clinical Oncology, 14, 399-416. https://doi.org/10.1038/nrclinonc.2016.217 |
| [12] | Cassetta, L. and Pollard, J.W. (2018) Targeting Macrophages: Therapeutic Approaches in Cancer. Nature Reviews Drug Discovery, 17, 887-904. https://doi.org/10.1038/nrd.2018.169 |
| [13] | Mantovani, A., Allavena, P., Marchesi, F., et al. (2022) Macrophages as Tools and Targets in Cancer Therapy. Nature Reviews Drug Discovery, 21, 799-820. https://doi.org/10.1038/s41573-022-00520-5 |
| [14] | Zhu, Y., Herndon, J.M., Sojka, D.K., et al. (2017) Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 47, 323-338.E6. https://doi.org/10.1016/j.immuni.2017.07.014 |
| [15] | Müller, A., Brandenburg, S., Turkowski, K., et al. (2015) Resident Microglia, and not Peripheral Macrophages, Are the Main Source of Brain Tumor Mononuclear Cells. International Journal of Cancer, 137, 278-288. https://doi.org/10.1002/ijc.29379 |
| [16] | Mantovani, A., Marchesi, F., Jaillon, S., et al. (2021) Tumor-Associated Myeloid Cells: Diversity and Therapeutic Targeting. Cellular & Molecular Immunology, 18, 566-578. https://doi.org/10.1038/s41423-020-00613-4 |
| [17] | Zuo, S., Song, J., Zhang, J., et al. (2021) Nano-Immunotherapy for Each Stage of Cancer Cellular Immunity: Which, Why, and What? Theranostics, 11, 7471-7487. https://doi.org/10.7150/thno.59953 |
| [18] | Guevara, M.L., Persano, F. and Persano, S. (2021) Nano-Immunotherapy: Overcoming Tumour Immune Evasion. Seminars in Cancer Biology, 69, 238-248. https://doi.org/10.1016/j.semcancer.2019.11.010 |
| [19] | Kiaie, S.H., Salehi-Shadkami, H., Sanaei, M.J., et al. (2023) Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy. Journal of Nanobiotechnology, 21, Article No. 339. https://doi.org/10.1186/s12951-023-02083-y |
| [20] | Lahooti, B., Akwii, R.G., Zahra, F.T., et al. (2023) Targeting Endothelial Permeability in the EPR Effect. Journal of Controlled Release, 361, 212-235. https://doi.org/10.1016/j.jconrel.2023.07.039 |
| [21] | Denardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 19, 369-382. https://doi.org/10.1038/s41577-019-0127-6 |
| [22] | Coussens, L.M., Zitvogel, L. and Palucka, A.K. (2013) Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? Science, 339, 286-291. https://doi.org/10.1126/science.1232227 |
| [23] | Moisan, F., Francisco, E.B., Brozovic, A., et al. (2014) Enhancement of Paclitaxel and Carboplatin Therapies by CCL2 Blockade in Ovarian Cancers. Molecular Oncology, 8, 1231-1239. https://doi.org/10.1016/j.molonc.2014.03.016 |
| [24] | Li, X., Yao, W., Yuan, Y., et al. (2017) Targeting of Tumour-Infiltrating Macrophages via CCL2/CCR2 Signalling as a Therapeutic Strategy against Hepatocellular Carcinoma. Gut, 66, 157-167. https://doi.org/10.1136/gutjnl-2015-310514 |
| [25] | Yoshimura, T., Li, C., Wang, Y., et al. (2023) The Chemokine Monocyte Chemoattractant Protein-1/CCL2 Is a Promoter of Breast Cancer Metastasis. Cellular & Molecular Immunology, 20, 714-738. https://doi.org/10.1038/s41423-023-01013-0 |
| [26] | Shen, S., Zhang, Y., Chen, K.G., et al. (2018) Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy. Molecular Pharmaceutics, 15, 3642-3653. https://doi.org/10.1021/acs.molpharmaceut.7b00997 |
| [27] | M？ckel, D., Bartneck, M., Niemietz, P., et al. (2024) CCL2 Chemokine Inhibition Primes the Tumor Vasculature for Improved Nanomedicine Delivery and Efficacy. Journal of Controlled Release, 365, 358-368. https://doi.org/10.1016/j.jconrel.2023.11.044 |
| [28] | Guo, F., Wang, Y., Liu, J., et al. (2016) CXCL12/CXCR4: A Symbiotic Bridge Linking Cancer Cells and Their Stromal Neighbors in Oncogenic Communication Networks. Oncogene, 35, 816-826. https://doi.org/10.1038/onc.2015.139 |
| [29] | Li, X., Bu, W., Meng, L., et al. (2019) CXCL12/CXCR4 Pathway Orchestrates CSC-Like Properties by CAF Recruited Tumor Associated Macrophage in OSCC. Experimental Cell Research, 378, 131-138. https://doi.org/10.1016/j.yexcr.2019.03.013 |
| [30] | Zannettino, A.C., Farrugia, A.N., Kortesidis, A., et al. (2005) Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. Cancer Research, 65, 1700-1709. https://doi.org/10.1158/0008-5472.CAN-04-1687 |
| [31] | Beider, K., Bitner, H., Leiba, M., et al. (2014) Multiple Myeloma Cells Recruit Tumor-Supportive Macrophages through the CXCR4/CXCL12 Axis and Promote Their Polarization toward the M2 Phenotype. Oncotarget, 5, 11283-11296. https://doi.org/10.18632/oncotarget.2207 |
| [32] | Ishida, Y., Kuninaka, Y., Yamamoto, Y., et al. (2020) Pivotal Involvement of the CX3CL1-CX3CR1 Axis for the Recruitment of M2 Tumor-Associated Macrophages in Skin Carcinogenesis. The Journal of Investigative Dermatology, 140, 1951-1961.E6. https://doi.org/10.1016/j.jid.2020.02.023 |
| [33] | Jung, K., Heishi, T., Khan, O.F., et al. (2017) Ly6Clo Monocytes Drive Immunosuppression and Confer Resistance to Anti-VEGFR2 Cancer Therapy. The Journal of Clinical Investigation, 127, 3039-3051. https://doi.org/10.1172/JCI93182 |
| [34] | Zhu, R., Su, L., Dai, J., et al. (2020) Biologically Responsive Plasmonic Assemblies for Second Near-Infrared Window Photoacoustic Imaging-Guided Concurrent Chemo-Immunotherapy. ACS Nano, 14, 3991-4006. https://doi.org/10.1021/acsnano.9b07984 |
| [35] | Zhang, F., Dong, J., Huang, K., et al. (2023) “Dominolike” Barriers Elimination with an Intratumoral Adenosine-Triphosphate-Supersensitive Nanogel to Enhance Cancer Chemoimmunotherapy. ACS Nano, 17, 18805-18817. https://doi.org/10.1021/acsnano.3c03386 |
| [36] | D’incalci, M. and Galmarini, C.M. (2010) A Review of Trabectedin (ET-743): A Unique Mechanism of Action. Molecular Cancer Therapeutics, 9, 2157-2163. https://doi.org/10.1158/1535-7163.MCT-10-0263 |
| [37] | Germano, G., Frapolli, R., Belgiovine, C., et al. (2013) Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 23, 249-262. https://doi.org/10.1016/j.ccr.2013.01.008 |
| [38] | Choi, T.H., Yoo, R.J., Park, J.Y., et al. (2024) Development of Finely Tuned Liposome Nanoplatform for Macrophage Depletion. Journal of Nanobiotechnology, 22, Article No. 83. https://doi.org/10.1186/s12951-024-02325-7 |
| [39] | Farzin, A., Etesami, S.A., Quint, J., et al. (2020) Magnetic Nanoparticles in Cancer Therapy and Diagnosis. Advanced Healthcare Materials, 9, e1901058. https://doi.org/10.1002/adhm.201901058 |
| [40] | Zanganeh, S., Hutter, G., et al. (2016) Iron Oxide Nanoparticles Inhibit Tumour Growth by Inducing Pro-Inflammatory Macrophage Polarization in Tumour Tissues. Nature Nanotechnology, 11, 986-994. https://doi.org/10.1038/nnano.2016.168 |
| [41] | Yu, G.-T., Rao, L., Wu, H., et al. (2018) Myeloid-Derived Suppressor Cell Membrane-Coated Magnetic Nanoparticles for Cancer Theranostics by Inducing Macrophage Polarization and Synergizing Immunogenic Cell Death. Advanced Functional Materials, 28, Article 1801389. https://doi.org/10.1002/adfm.201801389 |
| [42] | Shime, H., Matsumoto, M., Oshiumi, H., et al. (2012) Toll-Like Receptor 3 Signaling Converts Tumor-Supporting Myeloid Cells to Tumoricidal Effectors. Proceedings of the National Academy of Sciences of the United States of America, 109, 2066-2071. https://doi.org/10.1073/pnas.1113099109 |
| [43] | Huang, L., Xu, R., Li, W., et al. (2023) Repolarization of Macrophages to Improve Sorafenib Sensitivity for Combination Cancer Therapy. Acta Biomaterialia, 162, 98-109. https://doi.org/10.1016/j.actbio.2023.03.014 |
| [44] | Cao, S., Saw, P.E., Shen, Q., et al. (2022) Reduction-Responsive RNAi Nanoplatform to Reprogram Tumor Lipid Metabolism and Repolarize Macrophage for Combination Pancreatic Cancer Therapy. Biomaterials, 280, Article 121264. https://doi.org/10.1016/j.biomaterials.2021.121264 |
| [45] | Iwasaki, A. and Medzhitov, R. (2010) Regulation of Adaptive Immunity by the Innate Immune System. Science, 327, 291-295. https://doi.org/10.1126/science.1183021 |
| [46] | Demaria, O., Cornen, S., Da？ron, M., et al. (2019) Harnessing Innate Immunity in Cancer Therapy. Nature, 574, 45-56. https://doi.org/10.1038/s41586-019-1593-5 |
| [47] | Tajbakhsh, A., Gheibi Hayat, S.M., Movahedpour, A., et al. (2021) The Complex Roles of Efferocytosis in Cancer Development, Metastasis, and Treatment. Biomedicine & Pharmacotherapy, 140, Article 111776. https://doi.org/10.1016/j.biopha.2021.111776 |
| [48] | Logtenberg, M.E.W., Scheeren, F.A. and Schumacher, T.N. (2020) The CD47-SIRPα Immune Checkpoint. Immunity, 52, 742-752. https://doi.org/10.1016/j.immuni.2020.04.011 |
| [49] | Hayat, S.M.G., Bianconi, V., Pirro, M., et al. (2020) CD47: Role in the Immune System and Application to Cancer Therapy. Cellular Oncology, 43, 19-30. https://doi.org/10.1007/s13402-019-00469-5 |
| [50] | Liu, Y., Wang, Y., Yang, Y., et al. (2023) Emerging Phagocytosis Checkpoints in Cancer Immunotherapy. Signal Transduction and Targeted Therapy, 8, Article No. 104. https://doi.org/10.1038/s41392-023-01365-z |
| [51] | Shi, M., Gu, Y., Jin, K., et al. (2021) CD47 Expression in Gastric Cancer Clinical Correlates and Association with Macrophage Infiltration. Cancer Immunology, Immunotherapy, 70, 1831-1840. https://doi.org/10.1007/s00262-020-02806-2 |
| [52] | Yu, L., Ding, Y., Wan, T., et al. (2021) Significance of CD47 and Its Association with Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Frontiers in Immunology, 12, Article 768115. https://doi.org/10.3389/fimmu.2021.768115 |
| [53] | Hsieh, R.C., Krishnan, S., Wu, R.C., et al. (2022) ATR-Mediated CD47 and PD-L1 Up-Regulation Restricts Radiotherapy-Induced Immune Priming and Abscopal Responses in Colorectal Cancer. Science Immunology, 7, eabl9330. |
| [54] | Xu, X., Li, S., Yu, W., et al. (2024) Activation of RIG-I/MDA5 Signaling and Inhibition of CD47-SIRPα Checkpoint with a Dual siRNA-Assembled Nanoadjuvant for Robust Cancer Immunotherapy. Angewandte Chemie International Edition, 63, e202318544. https://doi.org/10.1002/anie.202318544 |
| [55] | Wang, S., Jiao, W., Yan, B., et al. (2024) Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRPα To Potentiate Antitumor Immunity. Nano Letters, 24, 2894-2903. https://doi.org/10.1021/acs.nanolett.4c00003 |
| [56] | Yoo, J.W., Irvine, D.J., Discher, D.E., et al. (2011) Bio-Inspired, Bioengineered and Biomimetic Drug Delivery Carriers. Nature Reviews Drug Discovery, 10, 521-535. https://doi.org/10.1038/nrd3499 |
| [57] | Kitada, T., Diandreth, B., Teague, B., et al. (2018) Programming Gene and Engineered-Cell Therapies with Synthetic Biology. Science, 359, eaad1067. https://doi.org/10.1126/science.aad1067 |
| [58] | Kerzel, T., Giacca, G., Beretta, S., et al. (2023) In Vivo Macrophage Engineering Reshapes the Tumor Microenvironment Leading to Eradication of Liver Metastases. Cancer Cell, 41, 1892-1910.E10. https://doi.org/10.1016/j.ccell.2023.09.014 |
| [59] | Hayden, P.J., Roddie, C., Bader, P., et al. (2022) Management of Adults and Children Receiving CAR T-Cell Therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 33, 259-275. https://doi.org/10.1016/j.annonc.2021.12.003 |
| [60] | Larson, R.C. and Maus, M.V. (2021) Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells. Nature Reviews Cancer, 21, 145-161. https://doi.org/10.1038/s41568-020-00323-z |
| [61] | Lei, A., Yu, H., Lu, S., et al. (2024) A Second-Generation M1-Polarized CAR Macrophage with Antitumor Efficacy. Nature Immunology, 25, 102-116. https://doi.org/10.1038/s41590-023-01687-8 |
| [62] | Nguyen, V.D., Min, H.K., Kim, D.H., et al. (2020) Macrophage-Mediated Delivery of Multifunctional Nanotherapeutics for Synergistic Chemo-Photothermal Therapy of Solid Tumors. ACS Applied Materials & Interfaces, 12, 10130-10141. https://doi.org/10.1021/acsami.9b23632 |
| [63] | Alizadeh, D., Zhang, L., Hwang, J., et al. (2010) Tumor-Associated Macrophages Are Predominant Carriers of Cyclodextrin-Based Nanoparticles into Gliomas. Nanomedicine: Nanotechnology, Biology and Medicine, 6, 382-390. https://doi.org/10.1016/j.nano.2009.10.001 |
| [64] | Pang, L., Zhu, Y., Qin, J., et al. (2018) Primary M1 Macrophages as Multifunctional Carrier Combined with PLGA Nanoparticle Delivering Anticancer Drug for Efficient Glioma Therapy. Drug Delivery, 25, 1922-1931. https://doi.org/10.1080/10717544.2018.1502839 |
| [65] | Li, J., Wu, Y., Wang, J., et al. (2023) Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function. ACS Nano, 17, 322-336. https://doi.org/10.1021/acsnano.2c07861 |
| [66] | Chen, S., Ma, T., Wang, J., et al. (2024) Macrophage-Derived Biomimetic Nanoparticles Enhanced SDT Combined with Immunotherapy Inhibited Tumor Growth and Metastasis. Biomaterials, 305, Article 122456. https://doi.org/10.1016/j.biomaterials.2023.122456 |
| [67] | Kalluri, R. and Lebleu, V.S. (2020) The Biology, Function, and Biomedical Applications of Exosomes. Science, 367, eaau6977. https://doi.org/10.1126/science.aau6977 |
| [68] | Wang, P., Wang, H., Huang, Q., et al. (2019) Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation. Theranostics, 9, 1714-1727. https://doi.org/10.7150/thno.30716 |
| [69] | Lu, Y., Han, G., Zhang, Y., et al. (2023) M2 Macrophage-Secreted Exosomes Promote Metastasis and Increase Vascular Permeability in Hepatocellular Carcinoma. Cell Communication and Signaling, 21, Article No. 299. https://doi.org/10.1186/s12964-022-00872-w |
| [70] | Xiong, F., Ling, X., Chen, X., et al. (2019) Pursuing Specific Chemotherapy of Orthotopic Breast Cancer with Lung Metastasis from Docking Nanoparticles Driven by Bioinspired Exosomes. Nano Letters, 19, 3256-3266. https://doi.org/10.1021/acs.nanolett.9b00824 |
